Quantib, a wholly-owned subsidiary of RadNet, is a key part of the company’s digital health strategy, with strong innovation in detecting prostate disease using artificial intelligence.
Quantib Prostate™ 3.0 is a state-of-the-art AI-based software solution that significantly improves the MRI prostate reporting workflow and its output for radiologists and urologists.
These features deliver outstanding reporting quality and speed, and a faster and more accurate diagnosis through the quick identification of abnormalities.
-
AI-based segmentation and volumetry
-
PSA density calculation
-
Precise registration and movement correction
-
PI-RADS scoring support
-
One-click segmentation of lesion candidates
“Quantib Prostate is much more helpful than I would have ever imagined given all the buzz about AI. But this buzz is real. This is truly a nice product.”
Edward Steiner, M.D.
The York/WellSpan Advanced Prostate Care Center
MRI now plays an increasingly important role in prostate cancer diagnosis, and Quantib’s FDA-cleared and CE-marked AI technology is proving invaluable for optimal patient outcomes.
Want to learn more?
To learn more about RadNet’s AI solution for Prostate MRI, click here.